The multicenter, double-blind AQUATIC trial found that adding aspirin to long-term oral anticoagulation in patients with chronic coronary syndrome and prior coronary stent implantation increased cardiovascular and all-cause mortality as well as major bleeding without reducing ischemic events. Among 872 patients followed for a median of 2.2 years, primary efficacy events occurred in 16.9% of those receiving aspirin versus 12.1% with placebo, while major bleeding occurred in 10.2% and 3.4%, respectively.

Source: The New England Journal of Medicine